ImmuneOnco Biopharmaceuticals (Shanghai) (1541) Fundamentals 2026 — Revenue Analysis | SniperIQ
ImmuneOnco Biopharmaceuticals (Shanghai) (1541) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
.40 on the HKSE. This SniperIQ fundamentals page covers ImmuneOnco Biopharmaceuticals (Shanghai)'s valuation, profitability (net margin -137.3%), revenue (¥150M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ImmuneOnco Biopharmaceuticals (Shanghai)'s market cap?
ImmuneOnco Biopharmaceuticals (Shanghai) (1541) has a market capitalization of approximately HK
.40 on the HKSE. Market cap moves with the live share price.What is ImmuneOnco Biopharmaceuticals (Shanghai)'s P/E ratio?
ImmuneOnco Biopharmaceuticals (Shanghai)'s trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ImmuneOnco Biopharmaceuticals (Shanghai)?
ImmuneOnco Biopharmaceuticals (Shanghai) runs a net profit margin of -137.3%, a gross margin of 94.8%, and an operating margin of -135.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ImmuneOnco Biopharmaceuticals (Shanghai) generate?
ImmuneOnco Biopharmaceuticals (Shanghai) reported revenue of ¥150M for fiscal year 2025, with net income of -¥213M and earnings per share (EPS) of -0.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ImmuneOnco Biopharmaceuticals (Shanghai) pay a dividend?
ImmuneOnco Biopharmaceuticals (Shanghai) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ImmuneOnco Biopharmaceuticals (Shanghai) financially healthy?
ImmuneOnco Biopharmaceuticals (Shanghai) carries a debt-to-equity ratio of 0.29x and a current ratio of 3.83x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ImmuneOnco Biopharmaceuticals (Shanghai) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ImmuneOnco Biopharmaceuticals (Shanghai) (1541) the key facts are: market cap HK
Track ImmuneOnco Biopharmaceuticals (Shanghai)'s full fundamentals live
Get ImmuneOnco Biopharmaceuticals (Shanghai)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.